This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Knopp, M. V. Articles by Choyke, P. L. Search for Related Content PubMed PubMed Citation Articles by Knopp, M. V. Articles by Choyke, P. L. Related Collections Therapeutics and Targets Therapeutics and Targets: Identification, Validation, and Markers Clinical Research: Imaging, Diagnosis, and Prognosis

Minireview

Functional Magnetic Resonance Imaging in Oncology for Diagnosis and Therapy Monitoring

The Ohio State University, Department of Radiology, Columbus, Ohio 43210-1228 [M. V. K., H. v. T-K.], and NIH, Clinical Center, Diagnostic Radiology Department, Bethesda, Maryland 20892-1182 [M. V. K., P. L. C.]

¹ To whom requests for reprints should be addressed, at Department of Radiology, The Ohio State University, University Hospitals, 163 Means Hall, 1654 Upham Drive, Columbus, OH 43210-1228. Phone: (614) 293-9227; Fax: (614) 866-9501; E-mail: Knopp-1{at}medctr.osu.edu

Functional magnetic resonance imaging is rapidly evolving as a capable noninvasive assessment tool for oncology to improve diagnosis and to monitor therapy. Current clinical techniques are based on microcirculation imaging using extracellular low molecular weight contrast agents such as gadopentetate dimeglumine and analogues. The temporal evolution of the enhancement visualizes the angiogenic properties of lesions with regard to vascular density and permeability, heterogeneity, and changes during therapy.

This article has been cited by other articles:

				A RADJENOVIC, B J DALL, J P RIDGWAY, and M A SMITH Measurement of pharmacokinetic parameters in histologically graded invasive breast tumours using dynamic contrast-enhanced MRI Br. J. Radiol., February 1, 2008; 81(962): 120 - 128. [Abstract] [Full Text] [PDF]

				S. Semple, R. Staff, S. Heys, T. Redpath, A. Welch, T. Ahearn, A. Hutcheon, and F. Gilbert Baseline MRI delivery characteristics predict change in invasive ductal breast carcinoma PET metabolism as a result of primary chemotherapy administration Ann. Onc., September 1, 2006; 17(9): 1393 - 1398. [Abstract] [Full Text] [PDF]

				A. G. Sorensen Magnetic Resonance As a Cancer Imaging Biomarker J. Clin. Oncol., July 10, 2006; 24(20): 3274 - 3281. [Abstract] [Full Text] [PDF]

				P. Workman, E. O. Aboagye, Y.-L. Chung, J. R. Griffiths, R. Hart, M. O. Leach, R. J. Maxwell, P. M. J. McSheehy, P. M. Price, and J. Zweit Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst, May 3, 2006; 98(9): 580 - 598. [Abstract] [Full Text] [PDF]

				U. De Giorgi and J. Verweij Imatinib and gastrointestinal stromal tumors: Where do we go from here? Mol. Cancer Ther., March 1, 2005; 4(3): 495 - 501. [Abstract] [Full Text] [PDF]